BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 24785277)

  • 1. [HER-2 overexpression and gene amplification of advanced breast cancers determined by fluorescence in situ hybridization in fine needle aspiration specimens].
    Zhang Z; Zhao L; Guo H; Guo L; Ling Y; Xu X; Zhao H; Pan Q
    Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):183-7. PubMed ID: 24785277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER-2/neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis.
    Beatty BG; Bryant R; Wang W; Ashikaga T; Gibson PC; Leiman G; Weaver DL
    Am J Clin Pathol; 2004 Aug; 122(2):246-55. PubMed ID: 15323142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Availability of fine needle aspirates for the assessment of HER2 gene amplification in invasive breast cancer patients].
    Lee JW; Noh WC; Kim MS; Kim HA; Chang YH; Hong YJ; Hong SI; Lee JK
    Korean J Lab Med; 2008 Oct; 28(5):392-9. PubMed ID: 18971621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y; Booser DJ; Sneige N
    Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
    Arihiro K; Oda M; Ogawa K; Tominaga K; Kaneko Y; Shimizu T; Matsumoto S; Oda M; Kurita Y; Taira Y
    Jpn J Clin Oncol; 2013 Jan; 43(1):55-62. PubMed ID: 23225912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era.
    Vocaturo A; Novelli F; Benevolo M; Piperno G; Marandino F; Cianciulli AM; Merola R; Donnorso RP; Sperduti I; Buglioni S; Mottolese M
    Oncologist; 2006 Sep; 11(8):878-86. PubMed ID: 16951391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].
    Zeng X; Liang ZY; Wu SF; Zhou WX; Gao J; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):584-8. PubMed ID: 17134563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
    Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
    Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reliability of immunocytochemistry and fluorescence in situ hybridization on fine-needle aspiration cytology samples of breast cancers: A comparative study.
    Acs B; Szekely N; Szasz AM; Lotz G; Szekely T; Istok R; Szekely E; Madaras L; Kulka J; Jaray B
    Diagn Cytopathol; 2016 Jun; 44(6):466-71. PubMed ID: 26990933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER-2 protein overexpressing breast cancer without gene amplification shows higher hormone receptor expression than HER-2 protein overexpressing breast cancer with gene amplification.
    Koo JS; Jung W; Yang WI
    Int J Surg Pathol; 2011 Aug; 19(4):425-32. PubMed ID: 19666946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER-2 gene amplification by fluorescence in situ hybridization (FISH) compared with immunohistochemistry (IHC) in breast cancer: a study of 528 equivocal cases.
    Zhang H; Ren G; Wang X; Zhao J; Yao H; Bai Y; Bo W
    Breast Cancer Res Treat; 2012 Jul; 134(2):743-9. PubMed ID: 22678158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Her-2/neu Oncogene Amplification by Fluorescence In Situ Hybridization and Protein Overexpression on Immunohistochemistry in Breast Cancer.
    Lateef F; Jamal S; Nasir S
    J Coll Physicians Surg Pak; 2018 Aug; 28(8):581-585. PubMed ID: 30060783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Her-2 amplification and p185 expression in invasive breast cancer cells in women].
    Titi S
    Ann Acad Med Stetin; 2006; 52(2):5-12. PubMed ID: 17633393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center.
    Murthy SS; Sandhya DG; Ahmed F; Goud KI; Dayal M; Suseela K; Rajappa SJ
    Indian J Pathol Microbiol; 2011; 54(3):532-8. PubMed ID: 21934215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
    Couturier J; Vincent-Salomon A; Nicolas A; Beuzeboc P; Mouret E; Zafrani B; Sastre-Garau X
    Mod Pathol; 2000 Nov; 13(11):1238-43. PubMed ID: 11106082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis.
    Gjerdrum LM; Sorensen BS; Kjeldsen E; Sorensen FB; Nexo E; Hamilton-Dutoit S
    J Mol Diagn; 2004 Feb; 6(1):42-51. PubMed ID: 14736826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
    Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
    Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
    Akhdar A; Bronsard M; Lemieux R; Geha S
    Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.
    Pauletti G; Dandekar S; Rong H; Ramos L; Peng H; Seshadri R; Slamon DJ
    J Clin Oncol; 2000 Nov; 18(21):3651-64. PubMed ID: 11054438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.